Metropolis Healthcare Ltd Q1 FY2025 Concall Summary

Key Takeaways

• Steady quarter, guidance intact: Revenue grew 13.1% YoY, landing within the 13%-15% guided range, while PAT jumped 31.3% on operating leverage. Full-year revenue and margin guidance were reaffirmed.
• B2C shift is the margin story: B2C revenue grew 18.4% and now contributes 54% of total revenue, up from 51% a year ago, driven by TruHealth bundling and direct-to-consumer channels that carry higher margins.
• Network expansion is a deliberate margin drag: The company is adding 25 labs and 500 centers this year, targeting 1,000 towns in 18 months; this creates roughly 1% EBITDA dilution from new-lab OpEx losses that will persist into FY26.
• Volume took a temporary hit from pricing: Patient volume growth of 7% was partially suppressed by a January 2024 B2C price increase, a pattern management calls normal for one or two quarters, with June volumes already recovering to 7.5% growth.
• What to watch next quarter: Whether the volume recovery from the price-increase dip sustains, the pace of B2C mix shift toward the 60% target, and any M&A announcement given management's stated focus on bolt-on deals.

Revenue Growth & Volume Dynamics

• Core growth engine: Revenue growth of 13.1% YoY was built on 7% patient volume growth and 6% from price increase and product mix change, with Q1 being a historically weaker quarter for West and South India.
• Volume dip from pricing action: The January 2024 B2C price increase caused a temporary one-to-two-quarter volume suppression, a pattern management describes as normal; month-on-month recovery was visible with June volumes growing 7.5%.
• Focus cities steady at high base: Top markets grew 8-11%, consistent over the last 2-3 quarters, while Mumbai delivered 18% growth and Pune and Surat also performed strongly.
• Institutional defocus a deliberate drag: Management consciously reduced exposure to government tenders, low-margin corporate accounts and aggregators; the remaining 9% institutional business grew slower than the company average, weighing on overall revenue in the short term.
• Growth ceiling is a strategic choice: Management argues growing at 25% would require playing in parts of the business that hurt margins, receivables and other KPIs, and that building on brand and science rather than discounting is the sustainable path.

Ameera Shah: "it is easy to build scale and grow at 25%, but you are not going to necessarily get the commensurate profit that actually makes this a business worth building or a business which is sticky enough and where you are building it on the back of brand and science rather than building it on the back of pure discount."

B2C Shift & TruHealth

• B2C now the majority: B2C revenue grew 18.4% YoY and now contributes 54% of total revenue, up from 51% in Q1 FY24, with faster-than-average growth in Bangalore, Pune and Surat. The stated target is 60%.
• TruHealth bundling drives upselling: Revenue from TruHealth wellness and illness packages grew 28% YoY, enabling higher revenue per patient and more tests per patient by upselling to existing customers.
• Pricing power rests on patient criticality: Management argues pricing is not commoditized by test type but by patient criticality; critical patients gravitate to trusted branded players where price has little meaning, and the direct-to-consumer and direct-to-doctor model keeps discount percentages stable.

Ameera Shah: "the pricing is completely impacted by the criticality of the patient. And the more critical the patient, the less chances they are willing to take on something going wrong, and the more chances that they will go to a branded player that they trust, and then price actually has very little meaning because you are doing testing once a year and you are average spending some Rs. 700, Rs. 800."

Network Expansion & New Lab Economics

• Rapid geographic rollout: Presence expanded to over 650 towns by Q1 end, up from 300 in FY23, with a goal of 1,000 towns over the next 18 months. Revenue from Tier-3 cities grew 18% YoY and now contributes more than 33% of total revenues.
• Expansion plan this year: The company plans to add 25 labs and 500 centers in FY25, focused on Tier-3 cities, all company-owned rather than franchisee-operated.
• New-lab margin dilution: New labs face low initial volumes while consumable kits must be consumed within a fixed period, creating roughly 1% EBITDA dilution that is already reflected in the P&L and expected to continue at a diminishing rate until full-year FY26, after which these labs should contribute positively.
• Gross margin masked by expansion: Despite B2C mix improvement, gross margin has not meaningfully expanded because new geographies have low initial volumes, new locations are expanding test menus, and new Specialty tests carry lower volume and higher cost initially. Management views these as worthwhile long-term investments.
• Entry science for new markets: The company assesses population, medical infrastructure, paying power and competition; starts with B2B presence; adds owned centers and B2C when volumes reach a threshold; and eventually establishes a lab when volumes justify it.

Margins & Cost Structure

• Margin expansion delivered: EBITDA grew 21.2% and PAT grew 31.3%, with operating leverage and operational efficiencies driving the expansion; OpEx increased only 10% while revenues grew 13%.
• Full-year margin guidance: EBITDA margin closed Q1 at 25%, within the guided 25%-26% range for FY25, with management expecting further expansion through the year from operating leverage and seasonal factors.
• Other expenses structurally lower: Other expenses declined sequentially due to a combination of seasonality and structural changes including automation, process improvement and productivity increases, though management did not quantify the split.
• New-lab dilution quantified: The anticipated 1% EBITDA dilution from new-lab OpEx losses is expected to continue at a lesser number until full-year FY26, after which it should cease and turn contributive.

B2B, Institutional & Competitive Dynamics

• B2B growth with discipline: B2B revenue grew 12.4% YoY while maintaining discount structure, contributing 37% of total revenue. Management claims increased market share in this segment.
• Institutional defocus is intentional: The company consciously reduced exposure to government tenders, low-margin corporate accounts and aggregators, accepting slower growth in the remaining 9% institutional slice to protect margins and receivables.
• Government receivables remain unresolved: The company continues to provide for revenues from Delhi government accounts; volumes from one account have declined this year, but services cannot be abruptly stopped given their public distribution nature.
• Competitive moat in illness: Management argues wellness-oriented health tech players lack doctor confidence, making it difficult for them to enter the illness space meaningfully, while Metropolis's direct-to-consumer and direct-to-doctor model insulates it from discount-driven competition.

Ameera Shah: "The wellness-oriented health tech players don't enjoy the same level of confidence from doctors, making it difficult for them to enter the illness space in any meaningful way."

M&A Strategy & Capital Allocation

• M&A a key focus: Ameera Shah is personally dedicating considerable time to identifying and pursuing bolt-on and strategic acquisitions.
• Three acquisition types: (1) geographical expansion to build leadership in fewer markets; (2) acquiring technical or medical skills in products, services and tests; (3) acquiring sub-scale or structurally challenged "zombie firms" that can be turned around with better management.
• Geographic preference for M&A: Preference is for North and East India, though management would not refrain from a good acquisition in South or West if it enabled market dominance.
• CAPEX Committee established: A new CAPEX Committee will oversee investments in infrastructure and technology to ensure efficient capital deployment.

Guidance & Commitments

Key Metrics